Psoriasis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma

As per DelveInsight's assessment, globally, Psoriasis pipeline constitutes 65+ key companies continuously working towards developing 75+ Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Psoriasis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Psoriasis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years.

*
Psoriasis companies working in the treatment market are AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others, are developing therapies for the Psoriasis treatment

*
Emerging Psoriasis therapies in the different phases of clinical trials are- Imsidolimab, TAK-279, Sonelokimab, Piclidenoson, QY101, SFA 002, RLS-1496, and others are expected to have a significant impact on the Psoriasis market in the coming years.

*
In August 2025, Bausch Health Americas Inc. announced a study to assess the safety, systemic exposure, and hypothalamic-pituitary-adrenal (HPA) axis suppression risk of topically applied IDP-118 lotion in pediatric patients with moderate to severe plaque psoriasis.

*
In June 2025, Sun Pharmaceutical Industries Limited released top-line findings from its Phase 2 clinical trial assessing the safety and efficacy of SCD-044, an innovative oral sphingosine-1-phosphate (S1P) receptor 1 agonist, in patients with moderate to severe psoriasis. The trial did not achieve its primary goal of demonstrating a 75% improvement in the Psoriasis Area and Severity Index (PASI greater than or equal to 75) at Week 16. This Phase 2 randomized, double-blind, placebo-controlled study involved 263 participants diagnosed with moderate to severe plaque psoriasis.

*
In May 2025, Johnson & Johnson (J&J) released updated findings from its Phase III ICONIC-TOTAL trial investigating icotrokinra, an oral peptide, for the treatment of plaque psoriasis (PsO). The randomized study included both adult and adolescent patients aged 12 years and older, with a body surface area involvement as low as 1% and moderate or greater psoriasis affecting key skin regions.

*
In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis. The LTE trial included the 52-week POETYK PSO-1 and POETYK PSO-2 studies, involving 1,221 participants who received a 6mg daily dose of open-label Sotyktu.

*
In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled study includes three dosing groups to evaluate the treatment's safety, pharmacokinetics, and tolerability. Participants will receive either 0.25mg, 0.5mg, or 1mg doses of VYN202, or a placebo, administered once daily over a 12-week period.

*
In December 2024, Bristol Myers Squibb (NYSE: BMY) announced findings from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials assessing the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary endpoint, demonstrating a significantly higher percentage of Sotyktu-treated patients attaining an ACR20 response-indicating at least a 20% improvement in disease signs and symptoms-after 16 weeks of treatment compared to placebo.

*
In October 2024, InnoCare Pharma has reported that its Phase II clinical trial of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for psoriasis treatment achieved the primary endpoint. The multicenter, randomized, double-blind, placebo-controlled study aimed to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients with moderate-to-severe plaque psoriasis.

*
In August 2024, Amgen (NASDAQ:AMGN) announced today that Otezla Registered (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are suitable candidates for phototherapy or systemic therapy. Currently, there are no other FDA-approved oral treatments for moderate to severe plaque psoriasis in this age group.

Psoriasis Overview

Psoriasis is a chronic autoimmune skin disorder that speeds up skin cell growth, causing red, scaly patches, itching, and inflammation.

Get a Free Sample PDF Report to know more about Psoriasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/psoriasis-pipeline-insight [https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:

*
Imsidolimab: AnaptysBio

*
TAK-279: Nimbus Lakshmi/Takeda

*
Sonelokimab: MoonLake Immunotherapeutics

*
Piclidenoson: Can-Fite Biopharma

*
Sonelokimab: MoonLake Immunotherapeutics

*
QY101: E-nitiate Biopharmaceuticals

*
SFA 002: SFA Therapeutics

*
RLS-1496: Rubedo Life Sciences, Inc

Psoriasis Emerging Therapy Assessment:

Imsidolimab: AnaptysBio

Imsidolimab, formerly called ANB019, is an antibody targeting the interleukin-36 receptor (IL-36R). AnaptysBio is developing it as a potential first-in-class treatment for patients with generalized pustular psoriasis (GPP).

TAK-279: Nimbus Lakshmi/Takeda

TAK-279 is a highly selective oral allosteric tyrosine kinase 2 inhibitor, designed to provide best-in-class treatment for psoriasis and other immune-mediated inflammatory conditions by targeting the non-receptor tyrosine-protein kinase. It is currently in Phase III clinical development for psoriasis.

Sonelokimab: MoonLake Immunotherapeutics

Sonelokimab (M1095) is an investigational trivalent bispecific nanobody that targets and neutralizes IL-17A, IL-17F, and IL-17A/F, offering potential in treating inflammatory diseases. Administered subcutaneously, it has shown clinical promise in driving disease modification for patients in dermatology and rheumatology.

Psoriasis Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Inhalation

*
Inhalation/Intravenous/Oral

*
Intranasal

*
Intravenous

*
Intravenous/ Subcutaneous

*
NA

*
Oral

*
Oral/intranasal/subcutaneous

*
Parenteral

*
Subcutaneous

Psoriasis Molecule Type

Psoriasis Products have been categorized under various Molecule types, such as

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Psoriasis Pipeline Therapeutics Assessment

*
Psoriasis Assessment by Product Type

*
Psoriasis By Stage and Product Type

*
Psoriasis Assessment by Route of Administration

*
Psoriasis By Stage and Route of Administration

*
Psoriasis Assessment by Molecule Type

*
Psoriasis by Stage and Molecule Type

DelveInsight's Psoriasis Report covers around 75+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Psoriasis Therapeutics Market include:

Key companies developing therapies for Psoriasis are - Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others.

Psoriasis Pipeline Analysis:

The Psoriasis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.

*
Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Psoriasis drugs and therapies [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Psoriasis Pipeline Market Drivers

*
Growing worldwide prevalence, ongoing research and development activities to identify novel and targeted therapies, increase in Awareness about the disease are some of the important factors that are fueling the Psoriasis Market.

Psoriasis Pipeline Market Barriers

*
However, poor adherence and compliance with medications, challenging disease in terms of management and other factors are creating obstacles in the Psoriasis Market growth.

Scope of Psoriasis Pipeline Drug Insight

*
Coverage: Global

*
Key Psoriasis Companies: Dermavant Sciences AnaptysBio, Nimbus Lakshmi/Takeda, MoonLake Immunotherapeutics, Can-Fite Biopharma, E-nitiate Biopharmaceuticals, SFA Therapeutics, Rubedo Life Sciences, Inc, and others

*
Key Psoriasis Therapies: Imsidolimab, TAK-279, Sonelokimab, Piclidenoson, QY101, SFA 002, RLS-1496, and others

*
Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies

*
Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers

Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Psoriasis Report Introduction

2. Psoriasis Executive Summary

3. Psoriasis Overview

4. Psoriasis- Analytical Perspective In-depth Commercial Assessment

5. Psoriasis Pipeline Therapeutics

6. Psoriasis Late Stage Products (Phase II/III)

7. Psoriasis Mid Stage Products (Phase II)

8. Psoriasis Early Stage Products (Phase I)

9. Psoriasis Preclinical Stage Products

10. Psoriasis Therapeutics Assessment

11. Psoriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Psoriasis Key Companies

14. Psoriasis Key Products

15. Psoriasis Unmet Needs

16 . Psoriasis Market Drivers and Barriers

17. Psoriasis Future Perspectives and Conclusion

18. Psoriasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriasis-pipeline-2025-latest-fda-approvals-clinical-trials-and-emerging-therapies-assessment-by-delveinsight-anaptysbio-nimbus-lakshmitakeda-moonlake-immunotherapeutics-canfite-biopharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.